Showing posts with label Pneumonia. Show all posts
Showing posts with label Pneumonia. Show all posts

Sunday, December 21, 2008

ACIP Provisional Recommendations for Use of Pneumococcal Vaccines

Moral of the story: Do you smoke? Are you asthmatic? Then get this vaccine! Smokers have been added to those who the CDC will recommend receive the vaccine to guard against a certain type of pneumonia.
  • smokers (19 and older)
  • asthmatics (19 and older)
  • People without a functioning spleen
  • Adults 65 and older
  • Anyone 2 and older with a weakened immune system (HIV, cancer
  • Anyone 2 and older with a chronic disease (diabetes, COPD, emphysema, sickle cell anemia, or any other heart, lung, kidney, or liver disease including alcoholics)
The vaccine is 23-valent pneumococcal polysaccharide vacine (PPSV23). It protects against 23 types of Streptococcus pneumoniae that cause a sever type of pneumonia that has a mortality rate near 20%. ACIP is the CDC's Advisory Committee on Immunization Practices - the CDC usually adopts their recommendations.

Provisional Recommendations for Use of Pneumococcal Vaccines

http://www.cdc.gov/vaccines/recs/provisional/downloads/pneumo-oct-2008-508.pdf

Date of ACIP vote: October 22, 2008
Date of posting of provisional recommendations: December 8, 2008
On October 22, 2008, the ACIP voted on new and revised recommendations for the use of 23-valent pneumococcal polysaccharide vaccine (PPSV23) for the prevention of invasive pneumococcal disease. The new provisional recommendations are as follows:

1. Recommendation for use of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) among adult cigarette smokers:
Adults who smoke cigarettes are at substantially increased risk for invasive pneumococcal disease. The ACIP recommends that cigarette smoking should be added to the list of indications for PPSV23 in adults aged 19 through 64 years. Proposed wording of the revised recommendation: Persons aged 19 through 64 years who smoke cigarettes should receive a single dose of PPSV23 and smoking cessation counseling.

2. Recommendation for use of PPSV23 among adults who have asthma:
Asthma is an independent risk factor for invasive pneumococcal disease. The ACIP recommends that asthma should be included among the chronic pulmonary diseases (such as COPD and emphysema) that are indications for PPSV23 in adults aged 19 through 64 years. Proposed wording of the revised recommendation: “Persons aged 19 through 64 years who have asthma should receive a single dose of PPSV23.”

Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients.

Moral of the story: Have a cholesterol problem? Taking Lipitor? Well, if you also happen to develop pneumonia your cholesterol meds will help you fight the disease. While there are clearly benefits to taking statins while you have pneumonia, you must be taking them from the start of the disease to see the benefit. There are many side effects to taking statins so there is probably no point in using this in a prophylactic manner (and they don't add statins to the drinking water, yet). However, one day you may be given statins on admission for pneumonia.

Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients.
Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, Sørensen HT.

Department of Clinical Epidemiology, Aarhus University and Aalborg Hospital, Forskningens Hus, Aalborg, Denmark. r.thomsen@rn.dk

BACKGROUND: While some experimental and clinical research suggests that statins improve outcomes after severe infections, the evidence for pneumonia is conflicting. We examined whether preadmission statin use decreased risk of death, bacteremia, and pulmonary complications after pneumonia.

METHODS: We conducted a population-based cohort study of 29,900 adults hospitalized with pneumonia for the first time between January 1, 1997, and December 31, 2004 in northern Denmark. Data on statin and other medication use, comorbidities, socioeconomic markers, laboratory findings, bacteremia, pulmonary complications, and death were obtained from medical databases. We used regression analyses to compute adjusted mortality rate ratios within 90 days and relative risks of bacteremia and pulmonary complications after hospitalization in both statin users and nonusers.

RESULTS: Of patients with pneumonia, 1371 (4.6%) were current statin users. Mortality among statin users was lower than among nonusers: 10.3% vs 15.7% after 30 days and 16.8% vs 22.4% after 90 days, corresponding to adjusted 30- and 90-day mortality rate ratios of 0.69 (95% confidence interval, 0.58-0.82) and 0.75 (0.65-0.86). Decreased mortality associated with statin use remained robust in various subanalyses and in a supplementary analysis using propensity score matching. In contrast, former use of statins and current use of other prophylactic cardiovascular drugs were not associated with decreased mortality from pneumonia. In statin users, adjusted relative risk for bacteremia was 1.07 (95% confidence interval, 0.69-1.67) and for pulmonary complications was 0.69 (0.42-1.14).

CONCLUSION: The use of statins is associated with decreased mortality after hospitalization with pneumonia.

Arch Intern Med. 2008 Oct 27;168(19):2081-7